Superworth

Diagnostics and research stocks with the fastest revenue growth

Revenue over the last twelve months against the twelve months before. As of .

Ranked
42
of 74 diagnostics and research stocks we cover
Median
+6.9%
Highest
+90.1%
BLLN
Range
−13.3% to +90.1%
median +6.9%
−13.3%+90.1%
#CompanyRevenue growthNet marginPrice to salesMarket cap
1BLLNBillionToOne+90.1%9.5%13.1×$5.2B
2CAICaris Life Sciences+85.4%10.6%9.2×$9.1B
3WATWaters+52.5%3.6%10.0×$46.4B
4GHGuardant Health+42.7%−38.3%20.0×$23.7B
5CDNACareDx+38.9%25.9%9.1×$4.5B
6NTRANatera+37.8%−7.1%20.7×$56.2B
7BDSXBiodesix+34.5%−27.0%2.2×$229.8M
8MEDPMedpace+24.7%17.7%6.5×$18.1B
9GRALGRAIL+23.1%n/m36.2×$6B
10QTRXQuanterix+22.0%−80.2%0.9×$132.9M
11XGNExagen+20.8%−26.6%2.9×$203.3M
12RDNTRadNet+18.9%−0.9%2.5×$5.8B
13VCYTVeracyte+17.3%20.4%7.0×$3.9B
14MASS908 Devices+13.4%−57.0%6.9×$422M
15IDXXIDEXX Laboratories+12.8%25.0%11.4×$52.1B
16NTLAIntellia Therapeutics+12.6%n/m27.5×$1.6B
17DGXQuest Diagnostics+9.1%9.5%2.3×$27.5B
18AAgilent Technologies+8.6%19.5%6.7×$49.6B
19TMOThermo Fisher Scientific+8.3%14.9%5.4×$256.9B
20IQVIQVIA+8.2%8.1%2.5×$42.5B
21MTDMettler-Toledo International+6.9%21.9%8.3×$34.2B
22FLGTFulgent Genetics+6.8%−26.0%1.6×$530.8M
23LHLabcorp+6.4%7.0%2.0×$28.9B
24DHRDanaher+5.5%16.9%6.3×$162.6B
25CTKBCytek Biosciences+5.4%−39.0%3.6×$750M
26ILMNIllumina+4.9%18.4%8.0×$35.7B
27RVTYRevvity+4.1%8.2%5.8×$16.9B
28CSTLCastle Biosciences+3.2%−5.4%3.0×$1.1B
29LNTHLantheus+2.3%17.7%4.2×$6.5B
30PACBPacific Biosciences of California+2.0%−82.5%4.6×$728.9M
31BRKRBruker+1.6%−2.0%2.4×$8.5B
32BIOBio-Rad Laboratories+1.4%8.6%3.8×$9.8B
33NRCNRC Health−0.2%4.2%3.8×$536.6M
34NEOGNeogen−0.3%−6.3%2.9×$2.6B
35CRLCharles River Laboratories International−0.7%−6.0%4.0×$16.2B
36HBIOHarvard Bioscience−1.1%−11.9%0.4×$39.1M
37AVTRAvantor−1.6%−8.8%1.6×$10.6B
38QDELQuidelOrtho−2.5%−39.2%0.4×$962.1M
39MYGNMyriad Genetics−3.2%−14.0%0.7×$559.6M
40FTREFortrea−3.4%−2.6%0.7×$1.9B
41TXG10x Genomics−4.3%−12.2%13.0×$8B
42PSNLPersonalis−13.3%n/m24.2×$1.7B

Not ranked: 23 with under $50M of revenue, 4 with not a meaningful number, 2 with a quarter missing. 3 companies whose data behind this number has a caveat are left out until it is checked.

A ranking of numbers, not a recommendation. A low multiple can be a bargain or a business in trouble: open the company to see which.

Revenue growth for other groups

Other rankings of diagnostics and research stocks

The group